DOI: 10.1111/imj.16255 ISSN: 1444-0903
ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease
Nada Hamad, Ian Bilmon, Lynette Chee, Andrea Henden, Anna Johnston, Duncan Purtill, Ashish Bajel, Siok‐Keen Tey, David Yeung, Theresa Cole, Clinton Lewis, Jason Butler- Internal Medicine
Abstract
This position paper provides an overview of the assessment and management of both acute and chronic graft‐versus‐host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid‐refractory and corticosteroid‐dependent GvHD.